

Freddie Hamdy

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8438926/freddie-hamdy-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

351
papers

18,967
citations

69
h-index

126
g-index

386
ext. papers

22,320
ext. citations

8
avg, IF

5.91
L-index

#	Paper	IF	Citations
351	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1415-1424	59.2	1451
350	Multiple newly identified loci associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2008 , 40, 316-21	36.3	722
349	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1425-1437	59.2	655
348	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013 , 45, 385-91, 391e1-2	36.3	413
347	Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult. <i>BMJ, The</i> , 2002 , 325, 766-70	5.9	388
346	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. <i>Nature Genetics</i> , 2009 , 41, 1116-21	36.3	360
345	MicroRNA in prostate, bladder, and kidney cancer: a systematic review. <i>European Urology</i> , 2011 , 59, 671-80.2	10.2	355
344	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018 , 50, 928-936	36.3	340
343	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014 , 46, 1103-9	36.3	331
342	High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. <i>Cancer Research</i> , 2010 , 70, 5163-73	10.1	296
341	Multiple loci with different cancer specificities within the 8q24 gene desert. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 962-6	9.7	283
340	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014 , 15, e484-92	21.7	277
339	Distinct microRNA alterations characterize high- and low-grade bladder cancer. <i>Cancer Research</i> , 2009 , 69, 8472-81	10.1	260
338	Multiple loci on 8q24 associated with prostate cancer susceptibility. <i>Nature Genetics</i> , 2009 , 41, 1058-60	36.3	252
337	Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2903-10	2.2	249
336	Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. <i>Nature Genetics</i> , 2011 , 43, 785-91	36.3	243
335	Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. <i>Prostate</i> , 1996 , 29, 231-40; discussion 241-2	4.2	228

334	Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. <i>Cancer Research</i> , 2012 , 72, 2814-21	10.1	227
333	A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. <i>Nature Genetics</i> , 2011 , 43, 1098-103	36.3	203
332	Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study. <i>Lancet Oncology, The</i> , 2008 , 9, 445-52	21.7	192
331	Effect of a Low-Intensity PSA-Based Screening Intervention on Prostate Cancer Mortality: The CAP Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 883-895	27.4	184
330	Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. <i>European Urology</i> , 2005 , 48, 386-99; discussion 398-9	10.2	183
329	Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. <i>Cancer Research</i> , 2002 , 62, 1619-23	10.1	182
328	Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. <i>BMJ, The</i> , 2012 , 344, d7894	5.9	163
327	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014 , 15, 1109-18	21.7	157
326	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <i>European Urology</i> , 2014 , 66, 489-99	10.2	156
325	A study based on whole-genome sequencing yields a rare variant at 8q24 associated with prostate cancer. <i>Nature Genetics</i> , 2012 , 44, 1326-9	36.3	151
324	Promoter hypermethylation identifies progression risk in bladder cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2046-53	12.9	150
323	Genome-wide association study identifies new prostate cancer susceptibility loci. <i>Human Molecular Genetics</i> , 2011 , 20, 3867-75	5.6	143
322	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2052-61	4	134
321	It's not just what you say, it's also how you say it: opening the 'black box' of informed consent appointments in randomised controlled trials. <i>Social Science and Medicine</i> , 2009 , 68, 2018-28	5.1	127
320	Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. <i>Clinical Cancer Research</i> , 2007 , 13, 1720-5	12.9	126
319	Genetic correction of PSA values using sequence variants associated with PSA levels. <i>Science Translational Medicine</i> , 2010 , 2, 62ra92	17.5	125
318	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 29-36	5.7	121
317	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. <i>Journal of Medical Genetics</i> , 2016 , 53, 800-811	5.8	121

316	Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	116
315	Circulating folate, vitamin B12, homocysteine, vitamin B12 transport proteins, and risk of prostate cancer: a case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1632-42	4	116
314	Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. <i>Oncogene</i> , 2003 , 22, 8699-706	9.2	113
313	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018 , 50, 682-692	36.3	112
312	Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. <i>British Journal of Cancer</i> , 2003 , 88, 1682-6	8.7	111
311	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. <i>Human Molecular Genetics</i> , 2013 , 22, 408-15	5.6	109
310	A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk. <i>Human Molecular Genetics</i> , 2013 , 22, 5056-64	5.6	107
309	Comparison of a Phytotherapeutic Agent (Permixon) with an α -Blocker (Tamsulosin) in the Treatment of Benign Prostatic Hyperplasia: A 1-Year Randomized International Study. <i>European Urology</i> , 2002 , 41, 497-507	10.2	107
308	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
307	Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study. <i>Contemporary Clinical Trials</i> , 2003 , 24, 272-82		106
306	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016 , 6, 1052-67	24.4	104
305	The intellectual challenges and emotional consequences of equipoise contributed to the fragility of recruitment in six randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 912-20	5.7	98
304	iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. <i>Journal of Proteome Research</i> , 2008 , 7, 897-907	5.6	95
303	FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. <i>European Urology</i> , 2009 , 55, 650-7	10.2	90
302	Use of macrophages to target therapeutic adenovirus to human prostate tumors. <i>Cancer Research</i> , 2011 , 71, 1805-15	10.1	90
301	Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up. <i>BJU International</i> , 2016 , 117, E10-9	5.6	90
300	Carotenoids, retinol, tocopherols, and prostate cancer risk: pooled analysis of 15 studies. <i>American Journal of Clinical Nutrition</i> , 2015 , 102, 1142-57	7	89
299	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. <i>Human Molecular Genetics</i> , 2013 , 22, 2520-8	5.6	88

298	BMP-regulated exosomes from <i>Drosophila</i> male reproductive glands reprogram female behavior. <i>Journal of Cell Biology</i> , 2014 , 206, 671-88	7.3	86
297	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ, The</i> , 2018 , 360, j5757	5.9	85
296	A Meta-analysis of Individual Participant Data Reveals an Association between Circulating Levels of IGF-I and Prostate Cancer Risk. <i>Cancer Research</i> , 2016 , 76, 2288-2300	10.1	85
295	Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases. <i>American Journal of Pathology</i> , 2007 , 170, 160-75	5.8	85
294	Combination of polymorphisms from genes related to estrogen metabolism and risk of prostate cancers: the hidden face of estrogens. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3596-602	2.2	83
293	Hypermethylation of CpG islands and shores around specific microRNAs and mirtrons is associated with the phenotype and presence of bladder cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 1287-96	12.9	82
292	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012 , 30, 149-55	4	81
291	Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2325-36	4	80
290	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019 , 76, 831-842	10.2	78
289	Understanding and Improving Recruitment to Randomised Controlled Trials: Qualitative Research Approaches. <i>European Urology</i> , 2017 , 72, 789-798	10.2	76
288	Systematic Review and Meta-analysis of Factors Determining Change to Radical Treatment in Active Surveillance for Localized Prostate Cancer. <i>European Urology</i> , 2015 , 67, 993-1005	10.2	75
287	Association of folate-pathway gene polymorphisms with the risk of prostate cancer: a population-based nested case-control study, systematic review, and meta-analysis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2528-39	4	75
286	Exploring treatment preferences facilitated recruitment to randomized controlled trials. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 1127-36	5.7	73
285	Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript. <i>Human Genetics</i> , 2011 , 129, 687-94	6.3	72
284	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010 , 16, 4374-81	12.9	72
283	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015 , 17, 789-95	8.1	70
282	Application of artificial intelligence to the management of urological cancer. <i>Journal of Urology</i> , 2007 , 178, 1150-6	2.5	69
281	Expression of Bcl-2, Bax, and p53 in high-grade prostatic intraepithelial neoplasia and localized prostate cancer: relationship with apoptosis and proliferation. <i>Prostate</i> , 1998 , 37, 223-9	4.2	68

280	Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. <i>Annals of Oncology</i> , 2015 , 26, 756-761	10.3	67
279	LYRIC/AEG-1 is targeted to different subcellular compartments by ubiquitinylation and intrinsic nuclear localization signals. <i>Clinical Cancer Research</i> , 2009 , 15, 3003-13	12.9	67
278	Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. <i>International Journal of Cancer</i> , 2008 , 122, 952-6	7.5	66
277	Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis. <i>European Urology</i> , 2020 , 78, 402-414	10.2	65
276	Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. <i>International Journal of Cancer</i> , 2003 , 105, 484-90	7.5	64
275	Population-based prostate-specific antigen testing in the UK leads to a stage migration of prostate cancer. <i>BJU International</i> , 2009 , 104, 1592-8	5.6	63
274	Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study). <i>Journal of Clinical Epidemiology</i> , 2003 , 56, 605-9	5.7	62
273	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021 , 53, 65-75	36.3	62
272	Microsatellite instability as predictor of survival in patients with invasive upper urinary tract transitional cell carcinoma. <i>Urology</i> , 2005 , 65, 1233-7	1.6	61
271	Psychological impact of prostate biopsy: physical symptoms, anxiety, and depression. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4235-41	2.2	60
270	Impact of prostate cancer testing: an evaluation of the emotional consequences of a negative biopsy result. <i>British Journal of Cancer</i> , 2010 , 102, 1335-40	8.7	60
269	Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2874-81	4	60
268	Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair. <i>Science Translational Medicine</i> , 2015 , 7, 312re11	17.5	59
267	Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions. <i>Human Pathology</i> , 2004 , 35, 1385-91	3.7	59
266	Artificial intelligence in predicting bladder cancer outcome: a comparison of neuro-fuzzy modeling and artificial neural networks. <i>Clinical Cancer Research</i> , 2003 , 9, 4172-7	12.9	59
265	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018 , 9, 2256	17.4	57
264	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015 , 26, 1603-16	2.8	56
263	Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. <i>International Journal of Cancer</i> , 2012 , 131, 1187-96	7.5	55

262	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 64-81		55
261	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015 , 24, 5589-602	5.6	54
260	Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. <i>Prostate</i> , 2010 , 70, 875-82	4.2	54
259	DNA-PKcs and PARP1 Bind to Unresected Stalled DNA Replication Forks Where They Recruit XRCC1 to Mediate Repair. <i>Cancer Research</i> , 2016 , 76, 1078-88	10.1	53
258	Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study). <i>International Journal of Cancer</i> , 2011 , 128, 440-6	7.5	53
257	Localization and quantification of mRNA for matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of matrix metalloproteinase-2 (TIMP-2) in human benign and malignant prostatic tissue. <i>Prostate</i> , 2000 , 42, 18-25	4.2	52
256	Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. <i>Journal of Urology</i> , 2006 , 175, 2323-30	2.5	51
255	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012 , 30, 181-7	4	50
254	Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMA study subset analysis. <i>European Urology</i> , 2004 , 45, 773-9; discussion 779-80	10.2	50
253	Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. <i>Prostate</i> , 2004 , 59, 304-10	4.2	50
252	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020 , 77, 320-330	10.2	50
251	iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer. <i>PLoS ONE</i> , 2012 , 7, e30885	3.7	48
250	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009 , 100, 1198-204	8.7	48
249	Screen-detected prostate cancer and the insulin-like growth factor axis: results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004 , 108, 887-92	7.5	47
248	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1121-9	4	46
247	Evaluating genetic risk for prostate cancer among Japanese and Latinos. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 2048-58	4	46
246	Prostate-specific antigen testing rates remain low in UK general practice: a cross-sectional study in six English cities. <i>BJU International</i> , 2011 , 108, 1402-8	5.6	46
245	Human prostate cancer cells express neuroendocrine cell markers PGP 9.5 and chromogranin A. <i>Prostate</i> , 2007 , 67, 1761-9	4.2	46

244	Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. <i>Prostate</i> , 2008 , 68, 661-74	4.2	46
243	Do height-related variations in insulin-like growth factors underlie the associations of stature with adult chronic disease?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 213-8	5.6	46
242	Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. <i>PLoS ONE</i> , 2010 , 5, e13485	3.7	46
241	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019 , 10, 431	17.4	45
240	NEURAL NETWORK ANALYSIS OF CLINICOPATHOLOGICAL AND MOLECULAR MARKERS IN BLADDER CANCER. <i>Journal of Urology</i> , 2000 , 163, 630-633	2.5	45
239	A recurrent truncating germline mutation in the BRIP1/FANCI gene and susceptibility to prostate cancer. <i>British Journal of Cancer</i> , 2009 , 100, 426-30	8.7	44
238	Circulating insulin-like growth factors and IGF-binding proteins in PSA-detected prostate cancer: the large case-control study ProtecT. <i>Cancer Research</i> , 2012 , 72, 503-15	10.1	44
237	Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. <i>BJU International</i> , 2008 , 101, 547-55	5.6	44
236	A comparison of the performance of microsatellite and methylation urine analysis for predicting the recurrence of urothelial cell carcinoma, and definition of a set of markers by Bayesian network analysis. <i>BJU International</i> , 2008 , 101, 1448-53	5.6	44
235	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015 , 75, 1467-74	4.4	43
234	Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-analysis. <i>International Journal of Cancer</i> , 2009 , 125, 1414-23	7.5	43
233	Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosis. <i>Journal of Bone and Mineral Research</i> , 2004 , 19, 1712-21	6.3	43
232	Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. <i>Prostate</i> , 2005 , 65, 322-30	4.2	43
231	Recent trends in the use of radical prostatectomy in England: the epidemiology of diffusion. <i>BJU International</i> , 2003 , 91, 331-6; discussion 336	5.6	42
230	Training recruiters to randomized trials to facilitate recruitment and informed consent by exploring patients' treatment preferences. <i>Trials</i> , 2014 , 15, 323	2.8	41
229	Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era. <i>Journal of Urology</i> , 2006 , 176, 439-49	2.5	40
228	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016 , 118, 869-879	5.6	38
227	Eight-plex iTRAQ analysis of variant metastatic human prostate cancer cells identifies candidate biomarkers of progression: An exploratory study. <i>Prostate</i> , 2010 , 70, 1313-32	4.2	38

226	Decision-making about PSA testing and prostate biopsies: a qualitative study embedded in a primary care randomised trial. <i>European Urology</i> , 2008 , 53, 1186-93	10.2	38
225	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016 , 7, 10979	17.4	37
224	Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. <i>European Urology</i> , 2016 , 70, 941-951	10.2	36
223	Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study). <i>International Journal of Cancer</i> , 2011 , 128, 1442-8	7.5	35
222	Bone morphogenetic protein- and mating-dependent secretory cell growth and migration in the Drosophila accessory gland. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 19292-7	11.5	35
221	Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. <i>BJU International</i> , 2006 , 98, 777-82	5.6	35
220	The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. <i>European Urology</i> , 2010 , 57, 398-406	10.2	34
219	The survival effect of prolactin on PC3 prostate cancer cells. <i>European Urology</i> , 2003 , 43, 301-8	10.2	33
218	Protease nexin 1 inhibits hedgehog signaling in prostate adenocarcinoma. <i>Journal of Clinical Investigation</i> , 2012 , 122, 4025-36	15.9	33
217	The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers. <i>BJU International</i> , 2013 , 111, 537-42	5.6	32
216	Contemporary accuracy of death certificates for coding prostate cancer as a cause of death: Is reliance on death certification good enough? A comparison with blinded review by an independent cause of death evaluation committee. <i>British Journal of Cancer</i> , 2016 , 115, 90-4	8.7	31
215	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. <i>British Journal of Cancer</i> , 2020 , 123, 1089-1100	8.7	30
214	Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. <i>Trials</i> , 2018 , 19, 50	2.8	30
213	Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage. <i>Cancer Research</i> , 2018 , 78, 3497-3509	10.1	30
212	The importance of dietary change for men diagnosed with and at risk of prostate cancer: a multi-centre interview study with men, their partners and health professionals. <i>BMC Family Practice</i> , 2014 , 15, 81	2.6	30
211	Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. <i>Cancer Causes and Control</i> , 2012 , 23, 347-54	2.8	30
210	Men with prostate cancer make positive dietary changes following diagnosis and treatment. <i>Cancer Causes and Control</i> , 2013 , 24, 1119-28	2.8	30
209	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. <i>PLoS Genetics</i> , 2014 , 10, e1004129	6	30

208	A cross-sectional analysis of the association between diet and insulin-like growth factor (IGF)-I, IGF-II, IGF-binding protein (IGFBP)-2, and IGFBP-3 in men in the United Kingdom. <i>Cancer Causes and Control</i> , 2012 , 23, 907-17	2.8	30
207	Screening for prostate cancer: an update. <i>European Urology</i> , 2008 , 53, 37-44	10.2	30
206	Gene expression assays. <i>Advances in Clinical Chemistry</i> , 2007 , 44, 247-92	5.8	30
205	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018 , 9, 4616	17.4	30
204	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016 , 14, 66	11.4	29
203	Identifying Ureters In Situ Under Fluorescence During Laparoscopic and Open Colorectal Surgery. <i>Annals of Surgery</i> , 2016 , 263, e1-2	7.8	29
202	Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case-control study. <i>Cancer Causes and Control</i> , 2015 , 26, 205-218	2.8	28
201	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. <i>European Urology</i> , 2019 , 76, 329-337	10.2	28
200	Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study. <i>Cancer Causes and Control</i> , 2013 , 24, 323-34	2.8	27
199	Adherence to dietary and lifestyle recommendations and prostate cancer risk in the prostate testing for cancer and treatment (ProtecT) trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2066-77	4	27
198	Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study. <i>International Journal of Cancer</i> , 2013 , 132, 2176-85	7.5	27
197	Neuro-fuzzy modeling: an accurate and interpretable method for predicting bladder cancer progression. <i>Journal of Urology</i> , 2006 , 175, 474-9	2.5	27
196	Considerations and methods for placebo controls in surgical trials (ASPIRE guidelines). <i>Lancet, The</i> , 2020 , 395, 828-838	40	26
195	Current vaccination strategies for prostate cancer. <i>European Urology</i> , 2012 , 61, 290-306	10.2	26
194	Associations of lower urinary tract symptoms with prostate-specific antigen levels, and screen-detected localized and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>BJU International</i> , 2008 , 102, 1400-6	5.6	26
193	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017 , 71, 381-388	10.2	25
192	Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 635-43	2.8	25
191	Glutamine deprivation alters the origin and function of cancer cell exosomes. <i>EMBO Journal</i> , 2020 , 39, e103009	13	25

190	Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. <i>Cancer Causes and Control</i> , 2020 , 31, 431-449	2.8	24
189	Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 1356-1365	4.1	24
188	STAGING OF PROSTATE CANCER USING 3-DIMENSIONAL TRANSRECTAL ULTRASOUND IMAGES: A PILOT STUDY. <i>Journal of Urology</i> , 1999 , 162, 1318-1321	2.5	24
187	Evaluation of association of HNF1B variants with diverse cancers: collaborative analysis of data from 19 genome-wide association studies. <i>PLoS ONE</i> , 2010 , 5, e10858	3.7	24
186	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. <i>Oncologist</i> , 2016 , 21, 716-22	5.7	24
185	Genome-wide association study of prostate cancer-specific survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 1796-800	4	23
184	Design and preliminary recruitment results of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP). <i>British Journal of Cancer</i> , 2014 , 110, 2829-36	8.7	23
183	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2014 , 32, 185-91	4	23
182	The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study. <i>Cancer Causes and Control</i> , 2010 , 21, 1829-42	2.8	23
181	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017 , 140, 75-85	7.5	22
180	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. <i>Cancer Prevention Research</i> , 2018 , 11, 687-696	3.2	21
179	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. <i>PLoS Genetics</i> , 2017 , 13, e1007001	6	20
178	Prostate cancer risk related to foods, food groups, macronutrients and micronutrients derived from the UK Dietary Cohort Consortium food diaries. <i>European Journal of Clinical Nutrition</i> , 2017 , 71, 274-283	5.2	20
177	Predictors of attendance for prostate-specific antigen screening tests and prostate biopsy. <i>European Urology</i> , 2012 , 62, 649-55	10.2	20
176	Predictors of 25-hydroxyvitamin D and its association with risk factors for prostate cancer: evidence from the prostate testing for cancer and treatment study. <i>Cancer Causes and Control</i> , 2012 , 23, 575-88	2.8	20
175	Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 104, 875-81	8.7	20
174	Associations of folate, vitamin B12, homocysteine, and folate-pathway polymorphisms with prostate-specific antigen velocity in men with localized prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2833-8	4	20
173	Identification of new genetic risk factors for prostate cancer. <i>Asian Journal of Andrology</i> , 2009 , 11, 49-55	2.8	20

172	Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2016 , 6, e011063	3	20
171	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. <i>Prostate</i> , 2019 , 79, 1079-1089	4.2	19
170	Does the introduction of prostate multiparametric magnetic resonance imaging into the active surveillance protocol for localized prostate cancer improve patient re-classification?. <i>BJU International</i> , 2018 , 122, 794-800	5.6	19
169	Physical activity, alcohol consumption, BMI and smoking status before and after prostate cancer diagnosis in the ProtecT trial: opportunities for lifestyle modification. <i>International Journal of Cancer</i> , 2015 , 137, 1509-15	7.5	19
168	Associations of circulating retinol, vitamin E, and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. <i>Cancer Causes and Control</i> , 2012 , 23, 1865-73	2.8	19
167	Using genetic proxies for lifecourse sun exposure to assess the causal relationship of sun exposure with circulating vitamin d and prostate cancer risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 597-606	4	19
166	Mutation analysis of the MSMB gene in familial prostate cancer. <i>British Journal of Cancer</i> , 2010 , 102, 4148-57	4.7	19
165	Neurofuzzy modeling to determine recurrence risk following radical cystectomy for nonmetastatic urothelial carcinoma of the bladder. <i>Clinical Cancer Research</i> , 2009 , 15, 3150-5	12.9	19
164	Screening for prostate cancer remains controversial. <i>Lancet, The</i> , 2009 , 374, 1482-3	40	19
163	A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study). <i>Contemporary Clinical Trials</i> , 2006 , 27, 413-9	2.3	19
162	Early diagnosis and surgical management of prostate cancer. <i>Cancer Treatment Reviews</i> , 2003 , 29, 151-60	4.4	19
161	Insertion of an SVA-E retrotransposon into the CASP8 gene is associated with protection against prostate cancer. <i>Human Molecular Genetics</i> , 2016 , 25, 1008-18	5.6	18
160	Serum insulin-like growth factor-I is positively associated with serum prostate-specific antigen in middle-aged men without evidence of prostate cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 163-5	4	18
159	Regulation of Dense-Core Granule Replenishment by Autocrine BMP Signalling in Drosophila Secondary Cells. <i>PLoS Genetics</i> , 2016 , 12, e1006366	6	18
158	Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. <i>Health Technology Assessment</i> , 2018 , 22, 1-96	4.4	18
157	Comparison of Prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: An Observational Cohort Study. <i>Journal of Urology</i> , 2019 , 201, 510-519	2.5	18
156	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016 , 139, 1520-33	7.5	18
155	Systematic Review of Studies Reporting Positive Surgical Margins After Bladder Neck Sparing Radical Prostatectomy. <i>Current Urology Reports</i> , 2017 , 18, 99	2.9	17

154	Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis. <i>PLoS ONE</i> , 2014 , 9, e110569	3.7	17
153	A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performance. <i>Journal of Clinical Epidemiology</i> , 2011 , 64, 628-36	5.7	17
152	Phenol sulfotransferase SULT1A1*2 allele and enhanced risk of upper urinary tract urothelial cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007 , 16, 2500-3	4	17
151	A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk. <i>Cancer Research</i> , 2019 , 79, 274-285	10.1	17
150	Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study. <i>European Urology</i> , 2008 , 53, 777-84	10.2	16
149	Low risk research using routinely collected identifiable health information without informed consent: encounters with the Patient Information Advisory Group. <i>Journal of Medical Ethics</i> , 2008 , 34, 37-40	2.5	16
148	Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trial. <i>BMJ, The</i> , 2007 , 335, 1139	5.9	16
147	Prostate-specific antigen (PSA) testing of men in UK general practice: a 10-year longitudinal cohort study. <i>BMJ Open</i> , 2017 , 7, e017729	3	16
146	Prostate-Specific Membrane Antigen-Guided Surgery. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 6-12	8.9	16
145	Validation of the Hospital Episode Statistics Outpatient Dataset in England. <i>Pharmacoeconomics</i> , 2016 , 34, 161-8	4.4	15
144	Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial. <i>BMJ Open</i> , 2015 , 5, e008953	3	15
143	PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2009 , 12, 296-300	6.2	15
142	Stage shift in PSA-detected prostate cancers - effect modification by Gleason score. <i>Journal of Medical Screening</i> , 2009 , 16, 98-101	1.4	15
141	Current strategies for monitoring men with localised prostate cancer lack a strong evidence base: observational longitudinal study. <i>British Journal of Cancer</i> , 2009 , 101, 390-4	8.7	15
140	Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy?. <i>European Journal of Cancer</i> , 2009 , 45, 2569-73	7.5	15
139	Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study. <i>British Journal of Cancer</i> , 2011 , 105, 931-7	8.7	15
138	Associations of lifestyle factors and anthropometric measures with repeat PSA levels during active surveillance/monitoring. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1877-85	4	15
137	DNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer. <i>Prostate</i> , 2007 , 67, 341-7	4.2	15

136	Novel biomarkers for the detection of prostate cancer. <i>Journal of Clinical Urology</i> , 2016 , 9, 3-10	0.2	15
135	Achievements and perspectives in prostate cancer phase 3 trials from genitourinary research groups in Europe: introducing the Prostate Cancer Consortium in Europe. <i>European Urology</i> , 2015 , 67, 904-12	10.2	14
134	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1731-1738	4	14
133	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial 2020 , 8,		14
132	Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?. <i>Cancer Causes and Control</i> , 2016 , 27, 1465-1474	2.8	14
131	Misclassification of outcome in case-control studies: Methods for sensitivity analysis. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 2377-2393	2.3	14
130	Molecular subtyping of bladder cancer using Kohonen self-organizing maps. <i>Cancer Medicine</i> , 2014 , 3, 1225-34	4.8	14
129	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020 , 125, 506-514	5.6	14
128	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021 , 12, 1236	17.4	14
127	Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	13
126	DNA damage response in peritumoral regions of oesophageal cancer microenvironment. <i>Carcinogenesis</i> , 2013 , 34, 139-45	4.6	13
125	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017 , 197, 607-613	2.5	13
124	Men's knowledge and attitudes towards dietary prevention of a prostate cancer diagnosis: a qualitative study. <i>BMC Cancer</i> , 2014 , 14, 812	4.8	13
123	PSA-detected prostate cancer and the potential for dedifferentiation--estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011 , 128, 1462-70	7.5	13
122	Feasibility and cost of obtaining informed consent for essential review of medical records in large-scale health services research. <i>Journal of Health Services Research and Policy</i> , 2009 , 14, 77-81	2.4	13
121	10-Year Outcomes in Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 180	59.2	12
120	Survival Among Men at High Risk of Disseminated Prostate Cancer Receiving Initial Locally Directed Radical Treatment or Initial Androgen Deprivation Therapy. <i>European Urology</i> , 2017 , 72, 345-351	10.2	12
119	Supporting prostate cancer survivors in primary care: Findings from a pilot trial of a nurse-led psycho-educational intervention (PROSPECTIV). <i>European Journal of Oncology Nursing</i> , 2018 , 32, 73-81	2.8	12

118	Curative radiation therapy in prostate cancer. <i>Acta Oncologica</i> , 2011 , 50 Suppl 1, 98-103	3.2	12
117	Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. <i>European Urology</i> , 2010 , 57, 446-52	10.2	12
116	Clinically localised prostate cancer is microsatellite stable. <i>BJU International</i> , 2007 , 99, 1031-5	5.6	12
115	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020 , 11, 3905	17.4	12
114	Factors distinguishing general practitioners who more readily participated in a large randomized trial were identified. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 67-73	5.7	11
113	Association between Prostinogen (KLK15) genetic variants and prostate cancer risk and aggressiveness in Australia and a meta-analysis of GWAS data. <i>PLoS ONE</i> , 2011 , 6, e26527	3.7	11
112	A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 175-83	0.9	11
111	Role of information in preparing men for transrectal ultrasound guided prostate biopsy: a qualitative study embedded in the ProtecT trial. <i>BMC Health Services Research</i> , 2015 , 15, 80	2.9	10
110	Overcoming difficulties with equipoise to enable recruitment to a randomised controlled trial of partial ablation vs radical prostatectomy for unilateral localised prostate cancer. <i>BJU International</i> , 2018 , 122, 970-977	5.6	10
109	The future of randomised controlled trials in urology. <i>European Urology</i> , 2014 , 66, 1-3	10.2	10
108	Very low PSA concentrations and deletions of the KLK3 gene. <i>Clinical Chemistry</i> , 2013 , 59, 234-44	5.5	10
107	Androgen regulates ADAMTS15 gene expression in prostate cancer cells. <i>Cancer Investigation</i> , 2010 , 28, 698-710	2.1	10
106	Prostate-specific antigen testing and prostate biopsy: are self-reported lower urinary tract symptoms and health-related quality of life associated with the decision to undergo these investigations?. <i>BJU International</i> , 2008 , 102, 1629-33	5.6	10
105	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , 2021 , 22, 1618-1631	21.7	10
104	The associations of anthropometric, behavioural and sociodemographic factors with circulating concentrations of IGF-I, IGF-II, IGFBP-1, IGFBP-2 and IGFBP-3 in a pooled analysis of 16,024 men from 22 studies. <i>International Journal of Cancer</i> , 2019 , 145, 3244-3256	7.5	9
103	Gleason drift in the NIHR ProtecT study. <i>Histopathology</i> , 2015 , 66, 438-46	7.3	9
102	Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. <i>International Journal of Cancer</i> , 2015 , 136, 1731-40	7.5	9
101	Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. <i>Cancer Causes and Control</i> , 2018 , 29, 383-388	2.8	9

100	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018 , 96, 35-46	5.7	9
99	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018 , 118, 266-276	8.7	9
98	Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies. <i>International Journal of Urology</i> , 2014 , 21, 786-92	2.3	9
97	Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study. <i>European Journal of Cancer</i> , 2009 , 45, 3254-61	7.5	9
96	The immunohistochemical detection of cripto-1 in benign and malignant human bladder. <i>Journal of Pathology</i> , 1998 , 185, 108-11	9.4	9
95	The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme. <i>BJU International</i> , 2007 , 100, 514-7	5.6	9
94	Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening. <i>Urology</i> , 2004 , 64, 317-22	1.6	9
93	Metabolic imbalance and prostate cancer progression. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2010 , 1, 248-71	0.9	9
92	The causal roles of vitamin B(12) and transcobalamin in prostate cancer: can Mendelian randomization analysis provide definitive answers?. <i>International Journal of Molecular Epidemiology and Genetics</i> , 2011 , 2, 316-27	0.9	9
91	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020 , 24, 1-176	4.4	9
90	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 208-216	4	9
89	Comparison of phytotherapy (Permixon [®]) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients 1996 , 29, 231		9
88	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018 , 199, 1470-1474	2.5	8
87	Mating induces switch from hormone-dependent to hormone-independent steroid receptor-mediated growth in <i>Drosophila</i> secondary cells. <i>PLoS Biology</i> , 2019 , 17, e3000145	9.7	8
86	Insulin-like growth factors (IGFs) and IGF-binding proteins in active monitoring of localized prostate cancer: a population-based observational study. <i>Cancer Causes and Control</i> , 2013 , 24, 39-45	2.8	8
85	PROSPECTIV-a pilot trial of a nurse-led psychoeducational intervention delivered in primary care to prostate cancer survivors: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2014 , 4, e005186 ³		8
84	Acupuncture in urological practice--a survey of urologists in England. <i>Complementary Therapies in Medicine</i> , 2011 , 19, 27-31	3.5	8
83	The handling and sampling of radical prostatectomy specimens for reporting and research: the Oxford approach. <i>Journal of Clinical Pathology</i> , 2012 , 65, 1057-61	3.9	8

82	Local anaesthetic transperineal (LAMP) prostate biopsy using a probe-mounted transperineal access system: a multicentre prospective outcome analysis. <i>BJU International</i> , 2021 , 128, 311-318	5.6	8
81	SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns. <i>Bioinformatics</i> , 2017 , 33, 822-833	7.2	8
80	Variation between specialist urologists in reporting extraprostatic extension after radical prostatectomy. <i>Journal of Clinical Pathology</i> , 2015 , 68, 465-72	3.9	7
79	Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial Lessons learnt from CAP (Cluster randomised trial of PSA testing for Prostate cancer). <i>BMC Medical Research Methodology</i> , 2015 , 15, 6	4.7	7
78	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. <i>BJU International</i> , 2013 , 111, 1148-55	5.6	7
77	Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP). <i>BMJ Open</i> , 2017 , 7, e015994	3	7
76	Associations of circulating 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and vitamin D pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. <i>European Journal of Cancer Prevention</i> , 2013 , 22, 121-5	2	7
75	Prostate cancer proteomics: The urgent need for clinically validated biomarkers. <i>Proteomics - Clinical Applications</i> , 2009 , 3, 197-212	3.1	7
74	Prostatic capsular incision during radical prostatectomy has important oncological implications: a systematic review and meta-analysis. <i>BJU International</i> , 2018 , 124, 554	5.6	6
73	Seasonal variation in prostate-specific antigen levels: a large cross-sectional study of men in the UK. <i>BJU International</i> , 2011 , 108, 1409-14	5.6	6
72	Psychological distress and prostate specific antigen levels in men with and without prostate cancer. <i>Brain, Behavior, and Immunity</i> , 2009 , 23, 1073-8	16.6	6
71	Flexible cystoscopy findings in patients investigated for profound lower urinary tract symptoms, recurrent urinary tract infection, and pain. <i>Journal of Endourology</i> , 2012 , 26, 1468-72	2.7	6
70	Less is more: artificial intelligence and gene-expression arrays. <i>Lancet, The</i> , 2004 , 364, 2003-4	40	6
69	Identification and diagnostic performance of a small RNA within the PCA3 and BMCC1 gene locus that potentially targets mRNA. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 268-75	4	5
68	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020 , 28, 1467-1475	5.3	5
67	Longitudinal prostate-specific antigen reference ranges: Choosing the underlying model of age-related changes. <i>Statistical Methods in Medical Research</i> , 2016 , 25, 1875-1891	2.3	5
66	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017 , 117, 734-743	8.7	5
65	The Use of Proteomics in Urological Research. <i>EAU Update Series</i> , 2005 , 3, 171-179		5

64	Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy. <i>PLoS ONE</i> , 2015 , 10, e0136735	3.7	5
63	Prostate-specific antigen patterns in US and European populations: comparison of six diverse cohorts. <i>BJU International</i> , 2016 , 118, 911-918	5.6	5
62	Estimating the sensitivity of a prostate cancer screening programme for different PSA cut-off levels: A UK case study. <i>Cancer Epidemiology</i> , 2018 , 52, 99-105	2.8	4
61	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011 , 35, 139-44	2.8	4
60	The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. <i>International Journal of Cancer</i> , 2007 , 121, 1958-66	7.5	4
59	The spectrum of prostate cancer care: from curative intent to palliation. <i>Current Urology Reports</i> , 2007 , 8, 245-52	2.9	4
58	The use of flow cytometry and RT-PCR in the detection of circulating PSA-positive cells in prostate cancer. <i>Methods in Molecular Biology</i> , 1998 , 92, 215-25	1.4	4
57	Transrectal ultrasound guided needle electromyography of the urethral sphincter in males. <i>Neurourology and Urodynamics</i> , 1995 , 14, 359-63	2.3	4
56	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1063-1070	8.7	4
55	A Systematic Review of Prostate Cancer Heterogeneity: Understanding the Clonal Ancestry of Multifocal Disease. <i>European Urology Oncology</i> , 2021 , 4, 358-369	6.7	4
54	Effect of green tea and lycopene on the insulin-like growth factor system: the ProDiet randomized controlled trial. <i>European Journal of Cancer Prevention</i> , 2019 , 28, 569-575	2	4
53	Characteristics of men responding to an invitation to undergo testing for prostate cancer as part of a randomised trial. <i>Trials</i> , 2016 , 17, 497	2.8	3
52	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018 , 34, 4141-4150	7.2	3
51	A model of the natural history of screen-detected prostate cancer. <i>British Journal of Cancer</i> , 2006 , 95, 1122-3	8.7	3
50	Development, validation and evaluation of an instrument for active monitoring of men with clinically localised prostate cancer: systematic review, cohort studies and qualitative study. <i>Health Services and Delivery Research</i> , 2015 , 3, 1-138	1.5	3
49	Glutamine Deprivation Regulates the Origin and Function of Cancer Cell Exosomes		3
48	Trends in Prostate Cancer Screening: Overview of the UK 2009 , 15-21		3
47	Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review. <i>European Urology Oncology</i> , 2021 , 4, 714-730	6.7	3

46	Transcriptomic and Functional Screens Reveal MicroRNAs That Modulate Prostate Cancer Metastasis. <i>Frontiers in Oncology</i> , 2020 , 10, 292	5.3	3
45	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 532-541	6.2	3
44	Detailed Molecular and Immune Marker Profiling of Archival Prostate Cancer Samples Reveals an Inverse Association between TMPRSS2:ERG Fusion Status and Immune Cell Infiltration. <i>Journal of Molecular Diagnostics</i> , 2020 , 22, 652-669	5.1	2
43	Factors associated with trial recruitment, preferences, and treatments received were elucidated in a comprehensive cohort study. <i>Journal of Clinical Epidemiology</i> , 2019 , 113, 200-213	5.7	2
42	Transurethral resection biopsy as part of a saturation biopsy protocol: a cohort study and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013 , 31, 542-8	2.8	2
41	Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial. <i>Cancer Causes and Control</i> , 2017 , 28, 877-888	2.8	2
40	Long-term quality of life in prostate cancer. <i>Lancet Oncology, The</i> , 2011 , 12, 832-3	21.7	2
39	Ethics of clinical trials from bayesian perspective: randomisation to clinical trials may solve dilemma of treatment choice in prostate cancer. <i>BMJ, The</i> , 2003 , 326, 1456	5.9	2
38	Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. <i>Oncotarget</i> , 2016 , 7, 1107-19	3.3	2
37	472: The Value of Repeat Serum PSA Measurements in the Detection of Prostate Cancer - Experience from the Feasibility Phase of the UK Protec Study. <i>Journal of Urology</i> , 2006 , 175, 153-153	2.5	2
36	Outreach and Influence of Surgical Societies' Recommendations on Minimally Invasive Surgery During the COVID-19 Pandemic-An Anonymized International Urologic Expert Inquiry. <i>Urology</i> , 2020 , 145, 73-78	1.6	2
35	Implications of celebrity endorsement of prostate cancer awareness in a tertiary referral unit - the 'Fry-Turnbull' effect. <i>BJU International</i> , 2020 , 125, 484-486	5.6	1
34	Targeting chemotherapy to advanced bladder cancer patients most likely to benefit. <i>Future Oncology</i> , 2010 , 6, 193-6	3.6	1
33	Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center: in regard to Kotwal et al. (Int J Radiat Oncol Biol Phys 2008;70:456-463). <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1681-2, author reply 1682	4	1
32	Endothelin and Skeletal Metastases in Hormone-Refractory Prostate Cancer. <i>European Urology Supplements</i> , 2003 , 2, 15-19	0.9	1
31	Safety and exceptional immunogenicity of novel 5T4 viral vectored vaccination regimes in early stage prostate cancer: a phase I clinical trial		1
30	Anti-androgens induce Rab11a-exosome secretion in prostate cancer by suppressing amino acid-sensitive PAT4-mTORC1 signalling		1
29	Prostate-Specific Antigen Testing for Prostate Cancer Screening-Is the Message Getting Through?. <i>JAMA Oncology</i> , 2021 ,	13.4	1

28	Systematic Review and Meta-Analysis of the Associations Between Body Mass Index, Prostate Cancer, Advanced Prostate Cancer and Prostate Specific Antigen		1
27	A genetic risk score to guide age-specific, personalized prostate cancer screening		1
26	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations		1
25	Mating Induces Switch From Hormone-Dependent to Independent Steroid Receptor-Mediated Growth in Drosophila Prostate-Like Cells		1
24	Prostate cancer cells home to bone in a new in vivo model of bone metastasis. <i>FASEB Journal</i> , 2009 , 23, 927-11	0.9	1
23	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. <i>BMJ Open</i> , 2020 , 10, e036024	3	1
22	Use of intraoperative fluorescence to enhance robot-assisted radical prostatectomy. <i>Future Oncology</i> , 2021 , 17, 1083-1095	3.6	1
21	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021 , 15, e2000025	3.1	1
20	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. <i>British Journal of Cancer</i> , 2021 , 125, 534-546	8.7	1
19	A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. <i>BMC Urology</i> , 2021 , 21, 18	2.2	1
18	Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients 1996 , 29, 231		1
17	Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.. <i>Science Advances</i> , 2022 , 8, eabf9096	14.3	1
16	Placebo comparator group selection and use in surgical trials: the ASPIRE project including expert workshop. <i>Health Technology Assessment</i> , 2021 , 25, 1-52	4.4	0
15	Population screening for prostate cancer 2018 , 171-182		
14	Reply to Behnam Shakiba's letter to the editor re: Philipp Dahm, James N'Dow, Lars Holmberg, Freddie Hamdy. The future of randomised controlled trials in urology. <i>Eur Urol</i> 2014;66:1-3. <i>European Urology</i> , 2014 , 66, e8	10.2	
13	Reducing Mortality in the Ageing Patient: Treatment of the Primary Tumour Is Not Necessary. <i>European Urology Focus</i> , 2017 , 3, 328-329	5.1	
12	Reply to Dennis Morrod's Letter to the Editor and Fritz H. Schröder's Reply to Dennis Morrod's Letter to the Editor re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A Risk-Based Strategy Improves Prostate-Specific Antigen-Driven Detection of Prostate Cancer. <i>Eur Urol</i> 2010 ;57:798-805. <i>European Urology</i> , 2010 , 58, 329-330	10.2	
11	Word of wisdom. Re: mortality results from the Göteborg randomised population-based prostate-cancer screening trial. <i>European Urology</i> , 2010 , 58, 940-1	10.2	

- 10 What are the practitioner-level determinants for inappropriate PSA testing?. *Nature Reviews Urology*, **2008**, 5, 70-1
- 9 The spectrum of prostate cancer care: From curative intent to palliation. *Current Prostate Reports*, **2008**, 6, 56-63
- 8 Re: Incidence of Initial Local Therapy Among Men with Lower-Risk Prostate Cancer in the United States. *European Urology*, **2006**, 50, 1368-1370 10.2
- 7 The Role of Genetic Instability in the Pathogenesis and Progression of Urothelial Carcinoma. *EAU Update Series*, **2005**, 3, 180-188
- 6 Screening for Prostate Cancer **2005**, 31-40
- 5 Staging in prostate cancer. *Expert Review of Anticancer Therapy*, **2002**, 2, 48-58 3.5
- 4 The Molecular Staging of Prostate Cancer **2003**, 793-809
- 3 Bone-Directed Therapy in Prostate Cancer: Rationale and Novel Approaches. *Translational Medicine Series*, **2006**, 223-236
- 2 Epidemiology, Pathology and Pathogenesis **2008**, 451-469
- 1 Intermediate-risk Prostate Cancer-A Sheep in Wolf's Clothing?. *European Urology Oncology*, **2021**, 6.7